ALK7:ActRIIB heteromultimers and uses thereof
US11827689B2 · kind B2 · utility
0Cited by
14References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 30, 2021 |
| Grant date | Nov 28, 2023 |
| Priority date | — |
| Expiry date | Sep 24, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK7 receptor and an extracellular domain of ActRIIB In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.